Boehringer Ingelheim’s lung cancer drug gets FDA fast track status
Under this designation, Boehringer Ingelheim will conduct a pivotal trial program in a patient group where prior treatment with reversible EGFR inhibitors has failed. Andreas Barner, member of
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.